Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease

S. Miyatake, N. Miyake, H. Touho, A. Nishimura-Tadaki, Y. Kondo, I. Okada, Y. Tsurusaki, H. Doi, H. Sakai, H. Saitsu, K. Shimojima, T. Yamamoto, M. Higurashi, N. Kawahara, H. Kawauchi, K. Nagasaka, N. Okamoto, T. Mori, S. Koyano, Y. KuroiwaM. Taguri, S. Morita, Y. Matsubara, S. Kure, N. Matsumoto

Research output: Contribution to journalArticlepeer-review

160 Citations (Scopus)

Abstract

Objective: RNF213 was recently reported as a susceptibility gene for moyamoya disease (MMD). Our aim was to clarify the correlation between the RNF213 genotype and MMD phenotype. Methods: The entire coding region of the RNF213 gene was sequenced in 204 patients with MMD, and corresponding variants were checked in 62 pairs of parents, 13 mothers and 4 fathers of the patients, and 283 normal controls. Clinical information was collected. Genotypephenotype correlations were statistically analyzed. Results: The c.14576G>A variant was identified in 95.1% of patients with familial MMD, 79.2% of patients with sporadic MMD, and 1.8% of controls, thus confirming its association with MMD, with an odds ratio of 259 and p < 0.001 for either heterozygotes or homozygotes. Homozygous c.14576G>A was observed in 15 patients but not in the controls and unaffected parents. The incidence rate for homozygotes was calculated to be >78%. Homozygotes had a significantly earlier age at onset compared with heterozygotes or wild types (median age at onset 3, 7, and 8 years, respectively). Of homozygotes, 60% were diagnosed with MMD before age 4, and all had infarctions as the first symptom. Infarctions at initial presentation and involvement of posterior cerebral arteries, both known as poor prognostic factors for MMD, were of significantly higher frequency in homozygotes than in heterozygotes and wild types. Variants other than c.14576G>A were not associated with clinical phenotypes. Conclusions: The homozygous c.14576G>A variant in RNF213 could be a good DNA biomarker for predicting the severe type of MMD, for which early medical/surgical intervention is recommended, and may provide a better monitoring and prevention strategy.

Original languageEnglish
Pages (from-to)803-810
Number of pages8
JournalNeurology
Volume78
Issue number11
DOIs
Publication statusPublished - 2012 Mar 13

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease'. Together they form a unique fingerprint.

Cite this